Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ciprofloxacin

FDA-approved product (injectable, injection), marketed as Cipro, Cipro In Dextrose 5% In Plastic Container, Cipro In Sodium Chloride 0.9% In Plastic Container and 8 more.

Registered studies
50+
Lab records
592
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ciprofloxacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Chronic bronchitis
  • Cystitis
  • Eye infection
  • Gonorrhea
  • Infection
  • Otitis externa
  • Prostatitis
  • Pyelonephritis
  • Sinusitis
  • Typhoid fever
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones; Antiinfectives
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA02; WHO ATC S01AE03

Repurposing investigation

Ciprofloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis92.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 118 of 130 lab records
  • E. coli: measured active in 134 of 137 lab records
  • K. pneumoniae: measured active in 264 of 294 lab records
  • M. tuberculosis: measured active in 29 of 31 lab records
Open Ciprofloxacin in ChEMBL Registered studies below
Show the latest 150 of 592 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ciprofloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Silver Nanoparticle-Reinforced Double Antibiotic Paste in Symptomatic Apical Periodontitis: A Randomized Controlled Trial

    NCT07762599 · start 2026-08-30

    Registered record
    Registry ID
    NCT07762599
    Conditions
    Apical Periodontitis; Post Endodontic Pain; Periapical Healing; Inflammatory Biomarkers
    Interventions
    silver nanoparticles reinforced double antibiotic paste; Double Antibiotic Paste
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-08-30
    Completion
    2027-12-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionApical Periodontitis; Post Endodontic Pain; Periapical Healing; Inflammatory Biomarkers
    Interventionsilver nanoparticles reinforced double antibiotic paste; Double Antibiotic Paste
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care

    NCT07236944 · start 2025-12

    Registered record
    Registry ID
    NCT07236944
    Conditions
    Febrile Urinary Tract Infection
    Interventions
    Pivmecillinam; Standard of Care (Investigator Choice)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-12
    Completion
    2029-03
    Enrolment
    560

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Urinary Tract Infection
    InterventionPivmecillinam; Standard of Care (Investigator Choice)
    PhasePhase 4
    Registry statusRecruiting

  • The Effect of Locally Dilvered Ciprofloxacine Loaded Injectable Platelet-rich Fibrin as an Adjunct to Non-surgical Periodontal Therapy on the Gingival Crevicular Level of Interleukin 6

    NCT06968286 · start 2025-01-01

    Registered record
    Registry ID
    NCT06968286
    Conditions
    Periodontitis Stage II
    Interventions
    SRP; SRP+Injectable platelet rich fibrin; SRP+ciprofloxacine loaded iPRF
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-01-01
    Completion
    2025-08-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriodontitis Stage II
    InterventionSRP; SRP+Injectable platelet rich fibrin; SRP+ciprofloxacine loaded iPRF
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis

    NCT06368804 · start 2024-09-15

    Registered record
    Registry ID
    NCT06368804
    Conditions
    Bronchiectasis
    Interventions
    Antibiotic monotherapy treatment and follow-up; Antibiotic bitherapy treatment and follow-up
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-09-15
    Completion
    2028-09-15
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchiectasis
    InterventionAntibiotic monotherapy treatment and follow-up; Antibiotic bitherapy treatment and follow-up
    PhasePhase 2
    Registry statusRecruiting

  • Effect of Hebal and Synthetic Medicamentss on Enterococcus Feacalis

    NCT06006663 · start 2023-08-26

    Registered record
    Registry ID
    NCT06006663
    Conditions
    Effective Intracanal Medicaments Against Enterococcus Faecalis
    Interventions
    Ibuprofen 400 mg.; modified triple antibiotic paste; curcumin; olive leaves extract
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2023-08-26
    Completion
    2023-12-10
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEffective Intracanal Medicaments Against Enterococcus Faecalis
    InterventionIbuprofen 400 mg.; modified triple antibiotic paste; curcumin; olive leaves extract
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension

    NCT05678621 · start 2022-11-30

    Registered record
    Registry ID
    NCT05678621
    Conditions
    Haematological Malignancy; Hypogammaglobulinemia
    Interventions
    trimethoprim-sulfamethoxazole (co-trimoxazole); amoxycillin/clavulanic acid and ciprofloxacin; Immunoglobulins
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2022-11-30
    Completion
    2027-04
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHaematological Malignancy; Hypogammaglobulinemia
    Interventiontrimethoprim-sulfamethoxazole (co-trimoxazole); amoxycillin/clavulanic acid and ciprofloxacin; Immunoglobulins
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Lesion Sterilization And Tissue Repair Versus Zinc Oxide And Eugenol For Treatment of Necrotic Primary Molars

    NCT05448937 · start 2022-10-01

    Registered record
    Registry ID
    NCT05448937
    Conditions
    Necrotic Primary Molars
    Interventions
    Lesion sterilization and tissue repair; zinc oxide and eugenol pulpectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2022-10-01
    Completion
    2025-03-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNecrotic Primary Molars
    InterventionLesion sterilization and tissue repair; zinc oxide and eugenol pulpectomy
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

    NCT05294588 · start 2022-04-18

    Registered record
    Registry ID
    NCT05294588
    Conditions
    Gonorrhea Male
    Interventions
    Cefixime; Ceftriaxone; Ciprofloxacin; Neisseria gonorrhoeae strain FA1090; Meningococcal Group B Vaccine; Influenza Vaccine; Tetanus-diptheria Vaccine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-04-18
    Completion
    2026-02-05
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonorrhea Male
    InterventionCefixime; Ceftriaxone; Ciprofloxacin; Neisseria gonorrhoeae strain FA1090 +3 more
    PhasePhase 2
    Registry statusCompleted

  • A Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia (FOVOCIP)

    NCT07616635 · start 2022-03-14

    Registered record
    Registry ID
    NCT07616635
    Conditions
    Haematopoietic Stem Cell Transplantation; Acute Leukemia
    Interventions
    Fosfomycin; ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-03-14
    Completion
    2024-12-01
    Enrolment
    177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHaematopoietic Stem Cell Transplantation; Acute Leukemia
    InterventionFosfomycin; ciprofloxacin
    PhasePhase 3
    Registry statusCompleted

  • Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia

    NCT04948463 · start 2021-11-15

    Registered record
    Registry ID
    NCT04948463
    Conditions
    Febrile Neutropenia
    Interventions
    Piperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection; Amikacin Injection; Ciprofloxacin; Piperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection; Amikacin Injection; Ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-11-15
    Completion
    2025-12-17
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    InterventionPiperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection +8 more
    PhasePhase 4
    Registry statusCompleted

  • Ciprofloxacin Utilization and Adverse Events Occurrence in Community Pharmacy Setting

    NCT05916105 · start 2021-09-01

    Registered record
    Registry ID
    NCT05916105
    Conditions
    Ciprofloxacin Adverse Reaction
    Interventions
    Ciprofloxacin Tablets
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-09-01
    Completion
    2022-03-01
    Enrolment
    151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCiprofloxacin Adverse Reaction
    InterventionCiprofloxacin Tablets
    PhaseNot recorded
    Registry statusCompleted

  • Susceptibility Testing of Biofilm to Guide Treatment of Periprosthetic Joint Infections

    NCT04488458 · start 2021-08-15

    Registered record
    Registry ID
    NCT04488458
    Conditions
    Prosthetic Joint Infection; Prosthetic Infection; Hip Prosthesis Infection; Knee Prosthesis Infection
    Interventions
    MIC or MBEC+MIC based treatment algorithm
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-08-15
    Completion
    2023-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProsthetic Joint Infection; Prosthetic Infection; Hip Prosthesis Infection; Knee Prosthesis Infection
    InterventionMIC or MBEC+MIC based treatment algorithm
    PhaseNot applicable
    Registry statusUnknown

  • Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018

    NCT03431675 · start 2019-03-01

    Registered record
    Registry ID
    NCT03431675
    Conditions
    Meningitis, Meningococcal
    Interventions
    Ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2019-03-01
    Completion
    2019-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningitis, Meningococcal
    InterventionCiprofloxacin
    PhasePhase 4
    Registry statusWithdrawn

  • Randomized Trial Comparing Prevena and ActiV.A.C. System to Convetional Care After Bascom's Cleft Lift Surgery

    NCT03458663 · start 2019-01-14

    Registered record
    Registry ID
    NCT03458663
    Conditions
    Pilonidal Disease
    Interventions
    Prevena™ og ACTIV.A.C™ Therapy System.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2019-01-14
    Completion
    2022-04-01
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPilonidal Disease
    InterventionPrevena™ og ACTIV.A.C™ Therapy System.
    PhaseNot applicable
    Registry statusTerminated

  • Otiprio Versus Ciprodex Tympanostomy Tube Outcomes

    NCT03347461 · start 2018-10

    Registered record
    Registry ID
    NCT03347461
    Conditions
    Otorrhea; Otitis Media With Effusion in Children
    Interventions
    Otiprio; Ciprodex
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2018-10
    Completion
    2019-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOtorrhea; Otitis Media With Effusion in Children
    InterventionOtiprio; Ciprodex
    PhasePhase 4
    Registry statusWithdrawn